Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing differentiated products in ophthalmology. The firm is focused on building its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on specialized therapeutic areas. Its products include ZIMED PF and PAUL GLAUCOMA IMPLANT. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease and is already available in over 40 countries around the world. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The firm is also developing REV-0100, which is in preclinical development as a treatment for Stargardt disease.
Follow-Up Questions
Aequus Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. Douglas Janzen은 2013부터 회사에 합류한 Aequus Pharmaceuticals Inc의 Chairman of the Board입니다.
AQSZF 주식의 가격 성능은 어떻습니까?
AQSZF의 현재 가격은 $0.0021이며, 전 거래일에 decreased 0% 하였습니다.
Aequus Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Aequus Pharmaceuticals Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
